NYSE:ANRO Alto Neuroscience (ANRO) Stock Price, News & Analysis $11.42 -0.68 (-5.62%) (As of 09/30/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Alto Neuroscience Stock (NYSE:ANRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alto Neuroscience alerts:Sign Up Key Stats Today's Range$10.99▼$12.0250-Day Range$8.22▼$15.1252-Week Range$7.91▼$24.00Volume317,019 shsAverage Volume220,683 shsMarket Capitalization$307.02 millionP/E RatioN/ADividend YieldN/APrice Target$33.80Consensus RatingBuy Company OverviewAlto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Read More… The Standard Oil of AI? (Ad)ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...Click here for the ticker >>> Alto Neuroscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks28th Percentile Overall ScoreANRO MarketRank™: Alto Neuroscience scored higher than 28% of companies evaluated by MarketBeat, and ranked 863rd out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAlto Neuroscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlto Neuroscience has only been the subject of 2 research reports in the past 90 days.Read more about Alto Neuroscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alto Neuroscience are expected to decrease in the coming year, from ($2.63) to ($2.74) per share.Read more about Alto Neuroscience's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.74% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Alto Neuroscience has recently increased by 6.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlto Neuroscience does not currently pay a dividend.Dividend GrowthAlto Neuroscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.74% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Alto Neuroscience has recently increased by 6.86%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.11 News SentimentAlto Neuroscience has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alto Neuroscience this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows4 people have added Alto Neuroscience to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Alto Neuroscience insiders have bought more of their company's stock than they have sold. Specifically, they have bought $152,069.00 in company stock and sold $0.00 in company stock.Read more about Alto Neuroscience's insider trading history. Receive ANRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address ANRO Stock News HeadlinesAnalysts Are Bullish on These NA Stocks: Alto Neuroscience, Inc. (ANRO), Rubrik, Inc. Class A (RBRK)September 11, 2024 | markets.businessinsider.comAlto Neuroscience Insiders Placed Bullish Bets Worth US$638.5kSeptember 11, 2024 | finance.yahoo.comMassive NVIDIA Sell-Off: Are We Headed for a Market Collapse?You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this year. But here's what's even more concerning...October 1, 2024 | Behind the Markets (Ad)Buy Rating Affirmed for Alto Neuroscience, Inc. Amid Promising ALTO-100 Clinical DevelopmentsSeptember 11, 2024 | markets.businessinsider.comWedbush Initiates Coverage of Alto Neuroscience (ANRO) with Outperform RecommendationSeptember 4, 2024 | msn.comAlto Neuroscience, Inc. (ANRO) Gets a Buy from JefferiesAugust 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alto Neuroscience, Inc. on Strong Clinical Trials and Strategic Precision Neuroscience ApproachAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed: Alto Neuroscience’s Promising Pipeline and Strong Financials Fuel Growth OptimismAugust 16, 2024 | markets.businessinsider.comSee More Headlines ANRO Stock Analysis - Frequently Asked Questions How have ANRO shares performed this year? Alto Neuroscience's stock was trading at $21.80 at the start of the year. Since then, ANRO stock has decreased by 47.6% and is now trading at $11.42. View the best growth stocks for 2024 here. How were Alto Neuroscience's earnings last quarter? Alto Neuroscience, Inc. (NYSE:ANRO) announced its earnings results on Tuesday, August, 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.07. When did Alto Neuroscience IPO? Alto Neuroscience (ANRO) raised $129 million in an initial public offering on Friday, February 2nd 2024. The company issued 8,040,000 shares at $16.00 per share. How do I buy shares of Alto Neuroscience? Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/13/2024Today10/01/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ANRO Previous SymbolNYSE:ANRO CUSIPN/A CIK1999480 Webwww.altoneuroscience.com Phone(650) 200-0412FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$33.80 High Stock Price Target$43.00 Low Stock Price Target$29.00 Potential Upside/Downside+196.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.04 Current Ratio19.85 Quick Ratio19.85 Sales & Book Value Annual Sales$210,000.00 Price / Sales1,461.98 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares26,884,000Free FloatN/AMarket Cap$307.02 million OptionableN/A BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NYSE:ANRO) was last updated on 10/1/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Web3 Could Send One Crypto SoaringVenture Capital corporations and blockchain funds are pouring money into Web3 gaming. And there's one littl...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredCentral Bank Abandons USDBillionaire investors are pouring capital into gold at rates never seen before… But what these wealthy "fat...True Gold Republic | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCharles Payne’s Secrets to Surviving 2024’s Volatile MarketCharles Payne Wants You Prepared for Q4 Because as we look toward 2025, there's no denying that market vola...Unstoppable Prosperity | SponsoredFDA’s hidden signal greenlights biotech winners — 97% of the timeThe FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.